Objective:To evaluate the therapeutic effect of Qinggan Huayu granule on mice with H22 liver cancer ascites tumor.Methods:A H22 liver cancer ascites mouse model was established by intraperitoneally injecting H22 liver...Objective:To evaluate the therapeutic effect of Qinggan Huayu granule on mice with H22 liver cancer ascites tumor.Methods:A H22 liver cancer ascites mouse model was established by intraperitoneally injecting H22 liver cancer cells.Mice were randomly divided into the model group,the Ganfule group(1.35 g/kg),the fluorouracil group(50 mg/kg i.p),the Qinggan Huayu granule groups at low(0.67 g/kg),medium(1.34 g/kg),and high(2.68 g/kg)doses.Then the mice were administered continuously for 10 days and body weight and abdominal circumference were monitored every 3 days.On day 11,eight rats in each group were randomly selected for dissection to detect the amount of peritoneal water,peritoneal permeability and histopathological changes.The remaining mice were observed for survival.In addition,the vascular endothelial growth factor A(VEGFA)and vascular endothelial growth factor receptor 2(VEGFR2)were determined by Western blotting.Results:Compared with the model group,the weight growth of mice in the fluorouracil group and the medium-dose and high-dose Qinggan Huayu granule groups was slower(P<0.05).Moreover,the abdominal circumference of mice in each treatment group was increased slowly.There were significant differences in abdominal circumference between the fluorouracil group,the medium-dose group and the control group from day 6(P<0.05)while the abdominal circumference of the high dose group was significantly smaller than that of the control group from day 12(P<0.05).Moreover,compared with the model group,the amount of ascites in the medium-and high-dose Qinggan Huayu granule groups was decreased significantly(P<0.05).The optical density value of ascites supernatant in medium-and high-dose Qinggan Huayu granule group and the fluorouracil group decreased significantly(P<0.05)and the survival period of the medium-dose Qinggan Huayu granule group and the fluorouracil group was prolonged prominently(P<0.05).There was no significant difference in the low-dose Qinggan Huayu granule group and the Ganfule group.Peritoneal histopathological assay showed more complete peritoneal structure,less edema and less angiogenesis of the peritoneum in the fluorouracil group and the medium-and high-dose Qinggan Huayu granule group,which was better than that of the Ganfule group and the low-dose group.Compared with the model group,the expressions of VEGFA and VEGFR2 in the medium-dose Qinggan Huayu granule group decreased significantly(P<0.05,P<0.01).Conclusion:Qinggan Huayu granule can inhibit ascites production in the mice model with H22 liver cancer ascites tumor,prolong the survival of mice,and reduce peritoneal permeability and suppress the increase of peritoneal neovascularization.The mechanism may be related to the inhibition of VEGF/VEGFR pathway.展开更多
目的:观察"治癌灵"穴位贴敷联合针刺对H22移植性肝癌小鼠肿瘤转移抑制基因Nm23-H1蛋白水平表达的调节作用,探讨该疗法对肿瘤的抑制作用是否与提高Nm23-H1的表达有关。方法:选取健康雄性昆明种小鼠50只,采取完全随机分组法,依...目的:观察"治癌灵"穴位贴敷联合针刺对H22移植性肝癌小鼠肿瘤转移抑制基因Nm23-H1蛋白水平表达的调节作用,探讨该疗法对肿瘤的抑制作用是否与提高Nm23-H1的表达有关。方法:选取健康雄性昆明种小鼠50只,采取完全随机分组法,依照随机数字表法选取10只小鼠,设为正常组,余者造模,经正常饲养7天后,随机分为模型组、穴位贴敷组、针刺组、综合组,每组10只。于雄性昆明种小鼠前肢右腋皮下接种0.2 m L H22肿瘤细胞悬液进行造模。计算瘤重和小鼠肿瘤生长抑制率,采用免疫组化法检测瘤细胞中Nm23-H1的含量。结果:与模型组比较,各组均能抑制瘤体生长(P<0.05),明显改善小鼠的生存质量,且综合组优于穴位贴敷组和针刺组(P<0.05);与模型组比较,各组均能明显提高Nm23-H1蛋白表达水平(P<0.01),综合组优于穴位贴敷组和针刺组(P<0.05)。结论:"治癌灵"穴位贴敷及针刺均可提高H22移植性肝癌小鼠Nm23-H1蛋白表达水平,进而抑制癌细胞的生长及肿瘤侵袭转移,改善生存质量,且穴位贴敷联合针刺疗法疗效更佳。展开更多
基金Fund Project:Beiing Municipal Science and Techoology Commission G20 Engineering Innovation Research for Ten Diseases Ten Drugs Research and Development Projec(N.Z171100001717008)National Key Research and Development Plan for Precision Medicine Research Key Phriject(No.2017YF0910002)。
文摘Objective:To evaluate the therapeutic effect of Qinggan Huayu granule on mice with H22 liver cancer ascites tumor.Methods:A H22 liver cancer ascites mouse model was established by intraperitoneally injecting H22 liver cancer cells.Mice were randomly divided into the model group,the Ganfule group(1.35 g/kg),the fluorouracil group(50 mg/kg i.p),the Qinggan Huayu granule groups at low(0.67 g/kg),medium(1.34 g/kg),and high(2.68 g/kg)doses.Then the mice were administered continuously for 10 days and body weight and abdominal circumference were monitored every 3 days.On day 11,eight rats in each group were randomly selected for dissection to detect the amount of peritoneal water,peritoneal permeability and histopathological changes.The remaining mice were observed for survival.In addition,the vascular endothelial growth factor A(VEGFA)and vascular endothelial growth factor receptor 2(VEGFR2)were determined by Western blotting.Results:Compared with the model group,the weight growth of mice in the fluorouracil group and the medium-dose and high-dose Qinggan Huayu granule groups was slower(P<0.05).Moreover,the abdominal circumference of mice in each treatment group was increased slowly.There were significant differences in abdominal circumference between the fluorouracil group,the medium-dose group and the control group from day 6(P<0.05)while the abdominal circumference of the high dose group was significantly smaller than that of the control group from day 12(P<0.05).Moreover,compared with the model group,the amount of ascites in the medium-and high-dose Qinggan Huayu granule groups was decreased significantly(P<0.05).The optical density value of ascites supernatant in medium-and high-dose Qinggan Huayu granule group and the fluorouracil group decreased significantly(P<0.05)and the survival period of the medium-dose Qinggan Huayu granule group and the fluorouracil group was prolonged prominently(P<0.05).There was no significant difference in the low-dose Qinggan Huayu granule group and the Ganfule group.Peritoneal histopathological assay showed more complete peritoneal structure,less edema and less angiogenesis of the peritoneum in the fluorouracil group and the medium-and high-dose Qinggan Huayu granule group,which was better than that of the Ganfule group and the low-dose group.Compared with the model group,the expressions of VEGFA and VEGFR2 in the medium-dose Qinggan Huayu granule group decreased significantly(P<0.05,P<0.01).Conclusion:Qinggan Huayu granule can inhibit ascites production in the mice model with H22 liver cancer ascites tumor,prolong the survival of mice,and reduce peritoneal permeability and suppress the increase of peritoneal neovascularization.The mechanism may be related to the inhibition of VEGF/VEGFR pathway.
文摘目的:观察"治癌灵"穴位贴敷联合针刺对H22移植性肝癌小鼠肿瘤转移抑制基因Nm23-H1蛋白水平表达的调节作用,探讨该疗法对肿瘤的抑制作用是否与提高Nm23-H1的表达有关。方法:选取健康雄性昆明种小鼠50只,采取完全随机分组法,依照随机数字表法选取10只小鼠,设为正常组,余者造模,经正常饲养7天后,随机分为模型组、穴位贴敷组、针刺组、综合组,每组10只。于雄性昆明种小鼠前肢右腋皮下接种0.2 m L H22肿瘤细胞悬液进行造模。计算瘤重和小鼠肿瘤生长抑制率,采用免疫组化法检测瘤细胞中Nm23-H1的含量。结果:与模型组比较,各组均能抑制瘤体生长(P<0.05),明显改善小鼠的生存质量,且综合组优于穴位贴敷组和针刺组(P<0.05);与模型组比较,各组均能明显提高Nm23-H1蛋白表达水平(P<0.01),综合组优于穴位贴敷组和针刺组(P<0.05)。结论:"治癌灵"穴位贴敷及针刺均可提高H22移植性肝癌小鼠Nm23-H1蛋白表达水平,进而抑制癌细胞的生长及肿瘤侵袭转移,改善生存质量,且穴位贴敷联合针刺疗法疗效更佳。
